So useful -thank you!
I filled in a form to contact him when I found out he's got one of these new roles of UK Parliament Thematic Research Lead for Health...
That's interesting. I would propose to set up a democratic process of some kind to create a shortlist of potential medications which could then...
I remembered wrongly...it was a trial of LDN for Long Covid I was alerted to, NOT Ampligen for ME. The researcher was Louis Nacul, who was...
yes, someone told me there was an ampligen trial planned, or even underway, but there were issues with supply of it. I wrote to the lead...
I thought Ampligen would be a possibility
The only reason I went for trialling medications was firstly that it hasn't been done properly in the past. LIFT seems to be a good template for...
Do you think it would help with a funding application to explicitly acknowledge that it is copying from LIFT, but maybe add in the commitment to...
Posts discussing trial methodology and possible drugs to trial have been moved from a thread about a specific trial The LIFT trial (OMF) -...
As I haven't heard back from Wiley, I did a chasing message yesterday (29 July 2024) Dear Wiley Publications Ethics Team (cc COPE, Deborah...
My latest gambit is to try complaining to Wiley (Cochrane's publisher) who had a research integrity guru called Chris Graf who wrote about the...
Ideally yes. However, I think prior stated views that the previous review was very badly done and biased and should be withdrawn would be...
Giving expert testimony not the same as writing a Cochrane review
OK will check their arguments. Why are Garner's arguments not specious? Is not OK to try and defend your work as being valid and useful? I think...
yes. OK. But the fact that Garner has to declare in the review that he has stated publicly that he thinks microclots are not the cause of long...
Sure. I should look back at what they wrote. I attended a meeting in July 2022 in Oxford where they presented their work and I got no impression...
There was no reason for Cochrane to do this review in the first place, apart from to rubbish Kell and Pretorius's exploratory work. Cochrane were...
Here's the latest correspondence with Cochrane. CEO Catherine Spencer wrote to me yesterday and I replied copying in COPE and Cochrane's Research...
Have heard from Cochrane CEO and replied. Will post tomorrow
I've now done this too.
Separate names with a comma.